Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) but reduced the price target from $51 to $45.

January 26, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst maintains Overweight rating on PTC Therapeutics but lowers price target from $51 to $45, indicating a positive outlook but with reduced expectations.
The Overweight rating suggests that Cantor Fitzgerald still has a positive outlook on PTC Therapeutics, implying potential outperformance in the market. However, the reduction in the price target may reflect a tempered expectation for the stock's future price appreciation. This could lead to a neutral short-term impact as the market digests the mixed signals of continued confidence in the stock's performance against a lower price target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80